Quarterly report pursuant to Section 13 or 15(d)

NONCONTROLLING INTEREST

v3.8.0.1
NONCONTROLLING INTEREST
3 Months Ended
Mar. 31, 2018
Noncontrolling Interest [Abstract]  
NONCONTROLLING INTEREST

NOTE 19 – NONCONTROLLING INTEREST

 

As of March 31, 2018, Dr. Yu Zhou, director and Co-Chief Executive Officer of GenExsome, who owned 40% of the equity interests of GenExosome, which is not under the Company’s control. The following is a summary of noncontrolling interest activities in the three months ended March 31, 2018.

 

    Amount  
Noncontrolling interest at December 31, 2017   $ (585,394 )
Net loss attributable to noncontrolling interest     (69,390 )
Foreign currency translation adjustment attributable to noncontrolling interest     160  
Noncontrolling interest at March 31, 2018   $ (654,624 )